<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000620</url>
  </required_header>
  <id_info>
    <org_study_id>123</org_study_id>
    <secondary_id>N01HC95178</secondary_id>
    <secondary_id>N01HC95179</secondary_id>
    <secondary_id>N01HC95180</secondary_id>
    <secondary_id>N01HC95181</secondary_id>
    <secondary_id>N01HC95182</secondary_id>
    <secondary_id>N01HC95183</secondary_id>
    <secondary_id>N01HC95184</secondary_id>
    <secondary_id>IAA#Y1HC9035</secondary_id>
    <secondary_id>IAA#Y1HC1010</secondary_id>
    <nct_id>NCT00000620</nct_id>
    <nct_alias>NCT00182910</nct_alias>
  </id_info>
  <brief_title>Action to Control Cardiovascular Risk in Diabetes (ACCORD)</brief_title>
  <acronym>ACCORD</acronym>
  <official_title>Action to Control Cardiovascular Risk in Diabetes (ACCORD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or
      cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic
      control, intensive blood pressure control, and multiple lipid management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Currently, about 17 million Americans have been diagnosed with diabetes and more than 90
      percent of them have type 2 diabetes. The number of people with this form of diabetes,
      formerly known as adult onset or non-insulin dependent diabetes, is growing rapidly. By 2050,
      the number of Americans with diagnosed diabetes is projected to increase by 165 percent to 29
      million, of whom 27 million will have the type 2 form. Cardiovascular disease (CVD) is the
      leading cause of death in people with type 2 diabetes; these individuals die of CVD at rates
      two to four times higher than those who do not have diabetes. They also experience more
      nonfatal heart attacks and strokes.

      Type 2 diabetes is associated with older age and is more common in those who are overweight
      or obese and have a family history of diabetes. Women with a history of diabetes during
      pregnancy, adults with impaired glucose tolerance, people with a sedentary lifestyle, and
      members of a minority race/ethnicity are also at a greater risk for developing type 2
      diabetes. African Americans, Hispanic/Latino Americans, American Indians, and some Asian
      Americans and Pacific Islanders are at particularly high risk for type 2 diabetes.

      DESIGN NARRATIVE:

      The three strategies tested in ACCORD included the following: (1) Blood sugar - ACCORD was
      designed to determine whether lowering blood glucose to a level closer to normal than called
      for in current guidelines reduces CVD risk. The study estimated effects on CVD of that level
      compared with a level that is usually targeted. (2) Blood pressure - many people with type 2
      diabetes have high blood pressure. The blood pressure part of the trial was designed to
      determine the effects of lowering blood pressure in the context of good blood sugar control,
      that is to determine whether lowering blood pressure to normal (systolic pressure less than
      120 mm Hg) will better reduce CVD risk, as compared to a usually-targeted level in current
      clinical practice (i.e., below the definition of hypertension; systolic pressure less than
      140 mm Hg). (3) Blood Fats - Many people with diabetes have high levels of LDL (&quot;bad&quot;)
      cholesterol and triglycerides, as well as low levels of HDL (&quot;good&quot;) cholesterol. ACCORD
      participants who are selected for this part of the trial were assigned to an intervention to
      improve blood fat levels. This part of the study looked at the effects of lowering LDL
      cholesterol and blood triglycerides and increasing HDL cholesterol compared to an
      intervention that only lowers LDL cholesterol, all in the context of good blood sugar
      control. A drug from a class of drugs called &quot;fibrates&quot; was used to lower triglycerides and
      increase HDL cholesterol, whereas a drug from the class of drugs called &quot;statins&quot; was used to
      lower LDL cholesterol.

      All ACCORD participants received blood sugar treatment from the study. Based on the second
      trial (Blood Pressure or Lipid) they were assigned to, participants also received their high
      blood pressure or cholesterol care from the study. Study participants received all medication
      and treatments related to the study free of charge. Individuals who selected for and
      consented to participate in the ACCORD study continued to see their personal physician for
      all other health care.

      In summary, the ACCORD Study was a double 2x2 factorial design with factors consisting of:
      intensive versus standard glycemic control, intensive versus standard blood pressure control,
      and blinded fenofibrate or placebo in combination with simvastatin to maintain desirable
      LDL-C levels. All 10,251 participants were randomized to the glycemic interventions; a
      subgroup of 4,733 participants who met the blood pressure entry criteria were randomized to
      the blood pressure interventions in one 2x2 trial; and a distinct subgroup of 5,518
      participants who met the lipid entry criteria were randomized to the lipid interventions in
      the second 2x2 trial. All participants had established type 2 diabetes and were recruited
      from 77 clinical centers in the United States (64 sites) and Canada (13 sites).

      On February 6, 2008, the National Heart, Lung and Blood Institute (NHLBI) announced that
      participants in the intensive glycemia treatment would be transitioned to the ACCORD standard
      glycemic treatment approach due to higher mortality in the intensive treatment group
      terminating the experimental arm of the Glycemia Trial early. The Blood Pressure and Lipid
      trials continued as designed to their planned termination in 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.</measure>
    <time_frame>4.9 years</time_frame>
    <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).
In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.</measure>
    <time_frame>4.7 years</time_frame>
    <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.</measure>
    <time_frame>4.7 years</time_frame>
    <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death From Any Cause in the Glycemia Trial.</measure>
    <time_frame>4.9 years</time_frame>
    <description>Time to death from any cause. Secondary measure for Glycemia Trial.
A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke in the Blood Pressure Trial.</measure>
    <time_frame>4.7 years</time_frame>
    <description>Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.</measure>
    <time_frame>4.7 years</time_frame>
    <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10251</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Glycemia Trial: intensive control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycemia Trial: standard control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BP Trial: intensive control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to &lt;120 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BP Trial: standard control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open label administration of multiple anti-hypertensive agents to maintain SBP level &lt;140 mm Hg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipid Trial: fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m2 in combination with open label simvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipid Trial: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR &lt;50 mL/min/1.73m2 in combination with open label simvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-hyperglycemic Agents</intervention_name>
    <description>Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control &lt;6%; standard control 7.0-7.9%).</description>
    <arm_group_label>Glycemia Trial: intensive control</arm_group_label>
    <arm_group_label>Glycemia Trial: standard control</arm_group_label>
    <other_name>glimepiride (Amaryl)</other_name>
    <other_name>metformin (Glucophage)</other_name>
    <other_name>repaglinide (Gluconorm, Prandin)</other_name>
    <other_name>rosiglitazone (Avandia)</other_name>
    <other_name>pioglitazone (Actos)</other_name>
    <other_name>human regular insulin (Novolin ge Toronto)</other_name>
    <other_name>human NPH (Novolin N)</other_name>
    <other_name>human mixed (Novolin 70/30)</other_name>
    <other_name>human isophane (Novolin ge NPH)</other_name>
    <other_name>human 30/70 (Novolin ge 30/70)</other_name>
    <other_name>insulin aspart (NovoRapid, NovoLog)</other_name>
    <other_name>insulin detemir (Levemir)</other_name>
    <other_name>human regular insulin (Novolin R)</other_name>
    <other_name>insulin glargine (Lantus)</other_name>
    <other_name>Acarbose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-hypertensive Agents</intervention_name>
    <description>Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control &lt;120 mm Hg; standard control &lt;140 mm Hg).</description>
    <arm_group_label>BP Trial: intensive control</arm_group_label>
    <arm_group_label>BP Trial: standard control</arm_group_label>
    <other_name>benazepril (Lotensin, Zestril, Altace)</other_name>
    <other_name>chlorthalidone (Thalitone)</other_name>
    <other_name>metoprolol (Toprol XL)</other_name>
    <other_name>diltiazem (Tiazac)</other_name>
    <other_name>plendil (Felodipine)</other_name>
    <other_name>terazosin (Hytrin)</other_name>
    <other_name>candesartan (Atacand)</other_name>
    <other_name>valsartan (Diovan)</other_name>
    <other_name>furosemide</other_name>
    <other_name>reserpine</other_name>
    <other_name>hydralazine</other_name>
    <other_name>carvedilol (Coreg)</other_name>
    <other_name>triamterene / hydrochlorothiazide (Dyazide)</other_name>
    <other_name>metoprolol / hydrochlorothiazide(Lopressor HCT)</other_name>
    <other_name>benazepril / hydrochlorothiazide (Lotensin HCT)</other_name>
    <other_name>lisinopril / hydrochlorothiazide (Zestoretic)</other_name>
    <other_name>candesartan / hydrochlorothiazide (Atacand HCT)</other_name>
    <other_name>valsartan / hydrochlorothiazide (Diovan HCT)</other_name>
    <other_name>amlodipine / benazepril (Lotrel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinded fenofibrate or placebo plus simvastatin</intervention_name>
    <description>Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.</description>
    <arm_group_label>Lipid Trial: fenofibrate</arm_group_label>
    <arm_group_label>Lipid Trial: placebo</arm_group_label>
    <other_name>fenofibrate (Tricor)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes
             Association guidelines, which include a fasting plasma glucose level greater than 126
             mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of
             greater than 200 mg/dl, with confirmation by a retest

          -  For participants aged 40 years or older, history of CVD (heart attack, stroke, history
             of coronary revascularization, history of peripheral or carotid revascularization, or
             demonstrated angina)

          -  For participants aged 55 years or older, a history of CVD is not required, but
             participant must be considered to be at high risk for experiencing a CVD event due to
             existing CVD, subclinical disease, or 2+ CVD risk factors

          -  HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Simons-Morton, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Friedewald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Byington, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University, Winston-Salem, NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis Medical Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accordtrial.org/</url>
    <description>Click here for the ACCORD trial web site</description>
  </link>
  <reference>
    <citation>Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):44i-55i. Epub 2007 Apr 16.</citation>
    <PMID>17599425</PMID>
  </reference>
  <reference>
    <citation>Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ; ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol. 2007 Jun 18;99(12A):112i-122i. Epub 2007 Apr 12.</citation>
    <PMID>17599421</PMID>
  </reference>
  <reference>
    <citation>Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KM, Nwachuku C, O'Connor PJ, Zhang P; ACCORD Study Group. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am J Cardiol. 2007 Jun 18;99(12A):90i-102i. Epub 2007 Apr 13.</citation>
    <PMID>17599429</PMID>
  </reference>
  <reference>
    <citation>Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, Fonseca VA, Hall K, Hramiak I, Miller ME, Osei K, Simons-Morton DG; ACCORD Study Group. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):80i-89i. Epub 2007 Apr 17.</citation>
    <PMID>17599428</PMID>
  </reference>
  <reference>
    <citation>Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, Margolis KL, Rosenberg Y, Sperl-Hillen JM, Vargo L, Williamson JD, Probstfield JL; ACCORD Study Group. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):68i-79i. Epub 2007 Apr 12.</citation>
    <PMID>17599427</PMID>
  </reference>
  <reference>
    <citation>Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL; ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):56i-67i. Epub 2007 Apr 12.</citation>
    <PMID>17599426</PMID>
  </reference>
  <reference>
    <citation>Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):4i-20i. Epub 2007 Apr 12. Review.</citation>
    <PMID>17599424</PMID>
  </reference>
  <reference>
    <citation>Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P; ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18;99(12A):34i-43i. Epub 2007 Apr 19.</citation>
    <PMID>17599423</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.</citation>
    <PMID>17599422</PMID>
  </reference>
  <reference>
    <citation>Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M; ACCORD Study Group. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol. 2007 Jun 18;99(12A):103i-111i. Epub 2007 Apr 13.</citation>
    <PMID>17599420</PMID>
  </reference>
  <results_reference>
    <citation>Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.</citation>
    <PMID>18539917</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 1999</study_first_submitted>
  <study_first_submitted_qc>October 27, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 1999</study_first_posted>
  <results_first_submitted>September 5, 2014</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Non-Insulin-Dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>ACCORD</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/accord</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/accord</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Forms</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/accord</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Manual of Procedures</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/accord</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants had established type 2 diabetes and were recruited from 77 clinical centers in the United States (64 sites) and Canada (13 sites). Recruitment occurred in two phases, from January to June 2001 and from February 2003 to October 2005.</recruitment_details>
      <pre_assignment_details>Eligible participants provided evidence of ability to routinely monitor capillary blood sugars from written records or electronic downloads from a self-monitoring blood glucose device (SMBG), or (in cases where such records could not be provided) underwent a 2 to 4-week pre-randomization run-in period to evaluate compliance with SMBG monitoring.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glycemia Trial: Intensive Control/BP Trial: Intensive Control</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
BP Trial - Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to &lt;120 mmHg. Anti-hypertensive agents include multiple anti-hypertensive medications as needed to reach Blood Pressure Trial arm-specific goals.</description>
        </group>
        <group group_id="P2">
          <title>Glycemia Trial: Intensive Control/BP Trial: Standard Control</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
BP Trial - Open label administration of multiple anti-hypertensive agents to maintain SBP level &lt;140 mm Hg. Anti-hypertensive agents include multiple anti-hypertensive medications as needed to reach Blood Pressure Trial arm-specific goals.</description>
        </group>
        <group group_id="P3">
          <title>Glycemia Trial: Intensive Control/Lipid Trial: Fenofibrate</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
Lipid Trial - Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2 in combination with open label simvastatin. Blinded fenofibrate or placebo plus simvastatin includes double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.</description>
        </group>
        <group group_id="P4">
          <title>Glycemia Trial: Intensive Control/Lipid Trial: Placebo</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR &lt;50 mL/min/1.73m^2 in combination with open label simvastatin. Blinded fenofibrate or placebo plus simvastatin includes double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.</description>
        </group>
        <group group_id="P5">
          <title>Glycemia Trial: Standard Control/BP Trial: Intensive Control</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
BP Trial - Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to &lt;120 mmHg. Anti-hypertensive agents include multiple anti-hypertensive medications as needed to reach Blood Pressure Trial arm-specific goals.</description>
        </group>
        <group group_id="P6">
          <title>Glycemia Trial: Standard Control/BP Trial: Standard Control</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
BP Trial - Open label administration of multiple anti-hypertensive agents to maintain SBP level &lt;140 mm Hg. Anti-hypertensive agents include multiple anti-hypertensive medications as needed to reach Blood Pressure Trial arm-specific goals (intensive control &lt;120 mm Hg; standard control &lt;140 mm Hg).</description>
        </group>
        <group group_id="P7">
          <title>Glycemia Trial: Standard Control/Lipid Trial: Fenofibrate</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
Lipid Trial - Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2 in combination with open label simvastatin. Blinded fenofibrate or placebo plus simvastatin includes double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.</description>
        </group>
        <group group_id="P8">
          <title>Glycemia Trial: Standard Control/Lipid Trial: Placebo</title>
          <description>Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR &lt;50 mL/min/1.73m^2 in combination with open label simvastatin. Blinded fenofibrate or placebo plus simvastatin includes double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1178"/>
                <participants group_id="P2" count="1193"/>
                <participants group_id="P3" count="1374"/>
                <participants group_id="P4" count="1383"/>
                <participants group_id="P5" count="1184"/>
                <participants group_id="P6" count="1178"/>
                <participants group_id="P7" count="1391"/>
                <participants group_id="P8" count="1370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1016"/>
                <participants group_id="P2" count="1057"/>
                <participants group_id="P3" count="1204"/>
                <participants group_id="P4" count="1205"/>
                <participants group_id="P5" count="1049"/>
                <participants group_id="P6" count="1026"/>
                <participants group_id="P7" count="1242"/>
                <participants group_id="P8" count="1224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="170"/>
                <participants group_id="P4" count="178"/>
                <participants group_id="P5" count="135"/>
                <participants group_id="P6" count="152"/>
                <participants group_id="P7" count="149"/>
                <participants group_id="P8" count="146"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="126"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="77"/>
                <participants group_id="P7" count="91"/>
                <participants group_id="P8" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missed closeout visit</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glycemia Trial: Intensive Control</title>
          <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
        </group>
        <group group_id="B2">
          <title>Glycemia Trial: Standard Control</title>
          <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5128"/>
            <count group_id="B2" value="5123"/>
            <count group_id="B3" value="10251"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="6.8"/>
                    <measurement group_id="B2" value="62.2" spread="6.8"/>
                    <measurement group_id="B3" value="62.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1983"/>
                    <measurement group_id="B2" value="1969"/>
                    <measurement group_id="B3" value="3952"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3145"/>
                    <measurement group_id="B2" value="3154"/>
                    <measurement group_id="B3" value="6299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="737"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4770"/>
                    <measurement group_id="B2" value="4744"/>
                    <measurement group_id="B3" value="9514"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nonwhite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1828"/>
                    <measurement group_id="B2" value="1819"/>
                    <measurement group_id="B3" value="3647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3300"/>
                    <measurement group_id="B2" value="3304"/>
                    <measurement group_id="B3" value="6604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4376"/>
                    <measurement group_id="B2" value="4367"/>
                    <measurement group_id="B3" value="8743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="752"/>
                    <measurement group_id="B2" value="756"/>
                    <measurement group_id="B3" value="1508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous cardiovascular disease (CVD) event</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of CVD event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1827"/>
                    <measurement group_id="B2" value="1782"/>
                    <measurement group_id="B3" value="3609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No history of CVD event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3301"/>
                    <measurement group_id="B2" value="3341"/>
                    <measurement group_id="B3" value="6642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.1"/>
                    <measurement group_id="B2" value="8.3" spread="1.1"/>
                    <measurement group_id="B3" value="8.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.2" spread="17.0"/>
                    <measurement group_id="B2" value="136.5" spread="17.2"/>
                    <measurement group_id="B3" value="136.4" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="10.6"/>
                    <measurement group_id="B2" value="75.0" spread="10.7"/>
                    <measurement group_id="B3" value="74.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.9" spread="34.0"/>
                    <measurement group_id="B2" value="104.9" spread="33.8"/>
                    <measurement group_id="B3" value="104.9" spread="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="11.8"/>
                    <measurement group_id="B2" value="41.9" spread="11.5"/>
                    <measurement group_id="B3" value="41.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156" lower_limit="105" upper_limit="230"/>
                    <measurement group_id="B2" value="154" lower_limit="108" upper_limit="226"/>
                    <measurement group_id="B3" value="155" lower_limit="106" upper_limit="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="B2" value="10" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="B3" value="10" lower_limit="5" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.</title>
        <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).
In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion.</description>
        <time_frame>4.9 years</time_frame>
        <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of MCE.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycemia Trial: Intensive Control</title>
            <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
          </group>
          <group group_id="O2">
            <title>Glycemia Trial: Standard Control</title>
            <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.</title>
          <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).
In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion.</description>
          <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of MCE.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5128"/>
                <count group_id="O2" value="5123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjustment performed for the following pre-specified factors: sub-trial assignment (Blood Pressure Trial or Lipid Trial), assignment to intensive BP group in BP Trial, assignment to fenofibrate group in Lipid Trial, the seven clinical center networks, and presence of clinical cardiovascular disease at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>P-value presented is not adjusted for multiple comparisons. A priori significance level was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death From Any Cause in the Glycemia Trial.</title>
        <description>Time to death from any cause. Secondary measure for Glycemia Trial.
A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid).</description>
        <time_frame>4.9 years</time_frame>
        <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycemia Trial: Intensive Control</title>
            <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
          </group>
          <group group_id="O2">
            <title>Glycemia Trial: Standard Control</title>
            <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
          </group>
        </group_list>
        <measure>
          <title>Death From Any Cause in the Glycemia Trial.</title>
          <description>Time to death from any cause. Secondary measure for Glycemia Trial.
A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid).</description>
          <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5128"/>
                <count group_id="O2" value="5123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjustment performed for the following pre-specified factors: sub-trial assignment (Blood Pressure Trial or Lipid Trial), assignment to intensive BP group in BP Trial, assignment to fenofibrate group in Lipid Trial, the seven clinical center networks, and presence of clinical cardiovascular disease at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>P-value presented is not adjusted for multiple comparisons. A priori significance level was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.</title>
        <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial.</description>
        <time_frame>4.7 years</time_frame>
        <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of MCE.</population>
        <group_list>
          <group group_id="O1">
            <title>BP Trial: Intensive Control</title>
            <description>Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to &lt;120 mmHg. Anti-hypertensive agents include multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals.</description>
          </group>
          <group group_id="O2">
            <title>BP Trial: Standard Control</title>
            <description>Open label administration of multiple anti-hypertensive agents to maintain SBP level &lt;140 mm Hg. Anti-hypertensive agents multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals.</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.</title>
          <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial.</description>
          <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of MCE.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Recruitment for the Blood PressureTrial was designed to enroll 4200 participant to have 94% power to detect a 20% reduction in the rate of MCE for patients in the intensive-therapy group as compared with the standard-therapy group, assuming a two-sided alpha level of 0.05, a primary-outcome rate of 4% per year in the standard-therapy group, and a planned average follow-up of approximately 5.6 years.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>P-value is adjusted for interim monitoring. A priori significance level was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Adjustment for the seven clinical center networks and presence of clinical cardiovascular disease at baseline as pre-specified in the study protocol.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke in the Blood Pressure Trial.</title>
        <description>Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial.</description>
        <time_frame>4.7 years</time_frame>
        <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of stroke.</population>
        <group_list>
          <group group_id="O1">
            <title>BP Trial: Intensive Control</title>
            <description>Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to &lt;120 mmHg. Anti-hypertensive agents include multiple anti-hypertensive medications as needed to reach Blood Pressure Trial arm-specific goals.</description>
          </group>
          <group group_id="O2">
            <title>BP Trial: Standard Control</title>
            <description>Open label administration of multiple anti-hypertensive agents to maintain SBP level to &lt;140 mm Hg. Anti-hypertensive agents include multiple anti-hypertensive medications as needed to reach Blood Pressure Trial arm-specific goals.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke in the Blood Pressure Trial.</title>
          <description>Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial.</description>
          <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of stroke.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>P-value presented is not adjusted for multiple comparisons. A priori significance level was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Adjustment for the seven clinical center networks and presence of clinical cardiovascular disease at baseline as pre-specified in the study protocol.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.</title>
        <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants.</description>
        <time_frame>4.7 years</time_frame>
        <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of MCE.</population>
        <group_list>
          <group group_id="O1">
            <title>Lipid Trial: Fenofibrate</title>
            <description>Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2, in combination with open label simvastatin 20 - 40 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Lipid Trial: Placebo</title>
            <description>Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m^2 or 54 mg/day in participants with eGFR &lt;50 mL/min/1.73m^2, in combination with open label simvastatin 20 - 40 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.</title>
          <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants.</description>
          <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior to occurrence of MCE.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2765"/>
                <count group_id="O2" value="2753"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Recruitment for the Glycemia Trial was designed to enroll 5800 participant to have 87% power to detect a 20% reduction in the rate of MCE for patients in the fenofibrate group as compared with the placebo group, assuming a two-sided alpha level of 0.05, a primary-outcome rate of 2.4% per year in the placebo group, and a planned average follow-up of approximately 5.6 years.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <p_value_desc>P-value is adjusted for interim monitoring. A priori significance level was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Adjustment for the seven clinical center networks and presence of clinical cardiovascular disease at baseline as pre-specified in the study protocol.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.</title>
        <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants.</description>
        <time_frame>4.7 years</time_frame>
        <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior occurrence of event.</population>
        <group_list>
          <group group_id="O1">
            <title>Lipid Trial: Fenofibrate</title>
            <description>Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m^2 or 54 mg/day in patients with eGFR &lt;50 mL/min/1.73m^2, in combination with open label simvastatin 20 - 40 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Lipid Trial: Placebo</title>
            <description>Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m^2 or 54 mg/day in participants with eGFR &lt;50 mL/min/1.73m^2, in combination with open label simvastatin 20 - 40 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.</title>
          <description>Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants.</description>
          <population>The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior occurrence of event.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2765"/>
                <count group_id="O2" value="2753"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641"/>
                    <measurement group_id="O2" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <p_value_desc>P-value presented is not adjusted for multiple comparisons. A priori significance level was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Adjustment for the seven clinical center networks and presence of clinical cardiovascular disease at baseline as pre-specified in the study protocol.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Includes Serious Adverse Events (SAEs) reported after randomization and throughout the planned observation period, mean follow-up was 4.9 years. Data on other (non-serious) adverse events were not collected.</time_frame>
      <desc>SAEs were defined as any adverse experience that was significantly life threatening and/or resulted in death, permanent disability, hospitalization or prolongation of hospitalization, myositis/myopathy, or hepatitis and were considered by the investigators to be possibly, probably, or definitely related to study treatments.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glycemia Trial: Intensive Control</title>
          <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels &lt;6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
        </group>
        <group group_id="E2">
          <title>Glycemia Trial: Standard Control</title>
          <description>Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Bradycardia, tachycardia, atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Angina/chest pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Hypoglycemia (fatal)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Hepatitis/liver failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Elevated creatinine, hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Severe fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Hyperosmolar nonketotic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Toxic metabolic enecphalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Blood dyscrasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Felodipine toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Motor vehicle accident (fatal)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Rhabdomyolisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute or chronic renal failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness, hypotension, syncope</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
              <event>
                <sub_title>Cerebrovacular accident</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tim Craven / Senior Biostatistician</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-6109</phone>
      <email>tcraven@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

